Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.

Mansoor LE, Yende-Zuma N, Baxter C, Mngadi KT, Dawood H, Gengiah TN, Samsunder N, Schwartz JL, Doncel GF, Abdool Karim Q.

J Int AIDS Soc. 2019 Sep;22(9):e25381. doi: 10.1002/jia2.25381.

2.

Social Harms in Female-INITIATED hiv prevention method RESEARCH: state of the evidence.

Montgomery ET, Roberts ST, Nel A, Malherbe M, Torjesen K, Bunge K, Singh D, Baeten JM, Marrazzo J, Chirenje ZM, Kabwigu S, Beigi R, Riddler SA, Gafoor Z, Reddy K, Mansoor LE, Nair L, Woeber K, Moodley J, Jeenarain N, Siva S, Naidoo L, Govender V, Palanee-Phillips T.

AIDS. 2019 Aug 12. doi: 10.1097/QAD.0000000000002346. [Epub ahead of print]

PMID:
31408030
3.

Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.

Montgomery ET, Stadler J, Naidoo S, Katz AWK, Laborde N, Garcia M, Reddy K, Mansoor LE, Etima J, Zimba C, Chitukuta M, Soto-Torres L.

AIDS. 2018 Jul 17;32(11):1517-1525. doi: 10.1097/QAD.0000000000001868.

PMID:
29957723
4.

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.

McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, Nagelkerke N, Garcia Lerma JG, Kashuba AD, Masson L, Mansoor LE, Karim QA, Karim SSA, Passmore JS.

Nat Med. 2018 May;24(4):491-496. doi: 10.1038/nm.4506. Epub 2018 Feb 26.

5.

Undue inducement: a case study in CAPRISA 008.

Mngadi KT, Singh JA, Mansoor LE, Wassenaar DR.

J Med Ethics. 2017 Dec;43(12):824-828. doi: 10.1136/medethics-2016-103414. Epub 2017 Mar 27.

PMID:
28348164
6.

Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women.

Liebenberg LJ, Masson L, Arnold KB, Mckinnon LR, Werner L, Proctor E, Archary D, Mansoor LE, Lauffenburger DA, Abdool Karim Q, Abdool Karim SS, Passmore JS.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):318-325. doi: 10.1097/QAI.0000000000001218.

7.

Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.

Govender EM, Mansoor LE, Abdool Karim Q.

AIDS Care. 2017 Jun;29(6):734-740. doi: 10.1080/09540121.2016.1248349. Epub 2016 Nov 1.

PMID:
27799005
8.

Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.

MacQueen KM, Dlamini S, Perry B, Okumu E, Sortijas S, Singh C, Pillay D, Majors A, Jerome S, Watson S, Karim SA, Karim QA, Mansoor LE.

AIDS Behav. 2016 Nov;20(11):2682-2691.

9.

Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants.

Selhorst P, Masson L, Ismail SD, Samsunder N, Garrett N, Mansoor LE, Abdool Karim Q, Abdool Karim SS, Passmore JS, Williamson C.

Clin Infect Dis. 2017 Jan 1;64(1):79-82. Epub 2016 Sep 29.

10.

Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators.

Upfold M, Grobler A, Suleman F, Mansoor LE.

AIDS Behav. 2017 Feb;21(2):462-469. doi: 10.1007/s10461-016-1465-z.

PMID:
27357499
11.

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.

Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group.

N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649.

12.

Genital inflammation and the risk of HIV acquisition in women.

Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q, Abdool Karim SS.

Clin Infect Dis. 2015 Jul 15;61(2):260-9. doi: 10.1093/cid/civ298. Epub 2015 Apr 21.

13.

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, Abdool Karim SS.

Trials. 2014 Dec 19;15:496. doi: 10.1186/1745-6215-15-496.

14.

The preventive misconception: experiences from CAPRISA 004.

Dellar RC, Abdool Karim Q, Mansoor LE, Grobler A, Humphries H, Werner L, Ntombela F, Luthuli L, Abdool Karim SS.

AIDS Behav. 2014 Sep;18(9):1746-52. doi: 10.1007/s10461-014-0771-6.

PMID:
24715227
15.

Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, Grobler A, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):811-9. doi: 10.1007/s10461-014-0751-x.

16.

Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study.

Gengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):833-40. doi: 10.1007/s10461-014-0750-y.

17.

Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Mansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, Amico KR, Fisher J, Fisher WA, Macqueen KM, Karim SS.

AIDS Behav. 2014 May;18(5):841-8. doi: 10.1007/s10461-014-0752-9.

18.

Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.

Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, Ngcobo N, Abdool Karim SS, Abdool Karim Q.

AIDS Behav. 2014 May;18(5):849-54. doi: 10.1007/s10461-014-0696-0.

19.

Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.

Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, Kashuba AD, Karim QA, Karim SS.

AIDS Behav. 2014 May;18(5):820-5. doi: 10.1007/s10461-014-0749-4.

20.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah TN, Moosa A, Naidoo A, Mansoor LE.

Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Epub 2013 Oct 16. Review.

21.

Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

Matthews LT, Sibeko S, Mansoor LE, Yende-Zuma N, Bangsberg DR, Karim QA.

PLoS One. 2013;8(3):e56400. doi: 10.1371/journal.pone.0056400. Epub 2013 Mar 5.

22.

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.

Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A.

AIDS Behav. 2013 Jul;17(6):2143-55. doi: 10.1007/s10461-013-0429-9. Review.

23.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
24.

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.

Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS.

Expert Opin Investig Drugs. 2012 May;21(5):695-715. doi: 10.1517/13543784.2012.667072. Epub 2012 Mar 7. Review.

25.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

26.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

27.

Medicines information and adherence in HIV/AIDS patients.

Mansoor LE, Dowse R.

J Clin Pharm Ther. 2006 Feb;31(1):7-15.

PMID:
16476115
28.

Effect of pictograms on readability of patient information materials.

Mansoor LE, Dowse R.

Ann Pharmacother. 2003 Jul-Aug;37(7-8):1003-9.

PMID:
12841808

Supplemental Content

Loading ...
Support Center